Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics

Journal of Medical Economics

Volumn 18, Issue 5, 2015, Pages 357-365

  Baser, Onur ^a   Xie, Lin ^a   Pesa, Jacqueline ^b   Durkin, Mike ^b  

^a STATINMED RESEARCH   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Healthcare cost; Hospitalization; Long acting antipsychotics; Oral atypical antipsychotics; Paliperidone palmitate; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; PALIPERIDONE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; SCHIZOPHRENIA; VETERANS HEALTH; ADOLESCENT; COMORBIDITY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG COMBINATION; ECONOMICS; GOVERNMENT; MIDDLE AGED; PATIENT ATTITUDE; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; PALIPERIDONE PALMITATE; PATIENT ACCEPTANCE OF HEALTH CARE; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; YOUNG ADULT;

EID: 84929092231     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.1001514     Document Type: Article

References (26)

1. Van OJ, Kapur S. Schizophrenia. Lancet 2009;374:635-45
2. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
3. Zhu B, Ascher-Svanum H, Faries DE, et al. Costs of treating patients with schizophrenia who have illness-related crisis events. BMC Psychiatry 2008;8:72-81
4. Schizophrenia. National Institute of Mental Health. http://www.nimh.nih.gov/health/publications/schizophrenia/schizophrenia-booket-2009.pdf. Accessed September 16, 2013
5. Almond S, Knap M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-51
6. Karve SJ, Panish JM, Dirani RG, et al. Health care utilization and costs among Medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses. Health Outcomes Res Med 2012;3:183-94
7. Chen EY, Hui CL, Dunn EL, et al. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophrenia Res 2005;77:99-104
8. Brown JD, Barrett A, Ireys H, et al. Evidence-based practices for Medicaid beneficiaries with Schizophrenia and Biopolar disorder. No. 7490. Mathematica Policy Research, 2012. http://aspe.hhs.gov/daltcp/reports/2012/ebpsbd.shtml. Accessed November 6, 2013
9. Seal KH, Berenthal D, Miner CR, et al. Bringing the war back home: mental health disorders among 103 788 US veterans returning from Iraq and Afghanistan seen at Department of Veterans Affairs facilities. Arch Intern Med 2007;167:476-82
10. United States Department of Veterans Affairs. VA medical centers. http://www.va.gov/health/. Accessed September 16, 2013
11. Xie L, Baser O. Clinical and economic burden of U.S. veteran schizophrenia patients: a real-world evaluation. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting. New Orleans, LA: May 18-22, 2013
12. Marder SR. Effective treatment for schizophrenia. United States Department of Veterans Affairs, http://www.hsrd.research.va.gov/publications/internal/pm-v7-n1.pdf. Accessed Sept 16, 2013
13. Mohamed S. Adaptation of intensive mental health intensive case management to rural communities in the Veterans Health Administration. Psychiatric Q 2013;84:103-14
14. O'Connor N. Book review: antipsychotic long-acting injections. Aust Psychiatry 2013;21:176-7
15. Schizophrenia 2013. DR/Decision Resources, LLC., Burlington, MA. 2013.
16. Achilla E, McCrone P. The cost-effectiveness of long-acting/extendedrelease antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy 2013;11:95-106
17. Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilization in patients with schizophrenia following initiation of risperidone longacting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009;12:317-24
18. Lafeuille MH, Gravel J, Lefebvre P, et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Medl Econ 2013;16:1290-9
19. Kozma, CM, Slaton T, Dirani R, et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open label extension. Curr Med Res Opin 2011;27:1603-11
20. Garcia-Ruiz AJ, Perez-Costillias L, Montesinos AC, et al. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev 2012;2:8-19
21. Edwards NC, Rupnow MF, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. PharmacoEconomics 2005;23:299-314
22. Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry 2008;7:16-27
23. Zhornitsky S, Strip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophrenia Res Treat 2012;2012:7171-82
24. Olivares JM, Rodriquez-Martinez A, Buron JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12-and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53
25. Lamoreaux J. The organizational structure for medical information management in the Department of Veterans Affairs. An overview of major health care databases. Med Care 1996;34:31-44
26. Imbens GW. Nonparametric estimation of average treatment effects under exogeneity: a review. Rev Econ Stat 2004;86:4-29